1. Home
  2. AZTR vs VRAX Comparison

AZTR vs VRAX Comparison

Compare AZTR & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AZTR
  • VRAX
  • Stock Information
  • Founded
  • AZTR 2014
  • VRAX 2013
  • Country
  • AZTR United States
  • VRAX United Kingdom
  • Employees
  • AZTR N/A
  • VRAX N/A
  • Industry
  • AZTR Biotechnology: Pharmaceutical Preparations
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • AZTR Health Care
  • VRAX Health Care
  • Exchange
  • AZTR Nasdaq
  • VRAX Nasdaq
  • Market Cap
  • AZTR 5.2M
  • VRAX 5.9M
  • IPO Year
  • AZTR 2023
  • VRAX 2022
  • Fundamental
  • Price
  • AZTR $0.30
  • VRAX $1.14
  • Analyst Decision
  • AZTR
  • VRAX Strong Buy
  • Analyst Count
  • AZTR 0
  • VRAX 1
  • Target Price
  • AZTR N/A
  • VRAX $3.00
  • AVG Volume (30 Days)
  • AZTR 280.4K
  • VRAX 123.9K
  • Earning Date
  • AZTR 05-08-2025
  • VRAX 02-05-2025
  • Dividend Yield
  • AZTR N/A
  • VRAX N/A
  • EPS Growth
  • AZTR N/A
  • VRAX N/A
  • EPS
  • AZTR N/A
  • VRAX N/A
  • Revenue
  • AZTR $7,500.00
  • VRAX $84,872.00
  • Revenue This Year
  • AZTR N/A
  • VRAX $5,169.18
  • Revenue Next Year
  • AZTR N/A
  • VRAX $66.97
  • P/E Ratio
  • AZTR N/A
  • VRAX N/A
  • Revenue Growth
  • AZTR N/A
  • VRAX 7.03
  • 52 Week Low
  • AZTR $0.23
  • VRAX $0.60
  • 52 Week High
  • AZTR $12.00
  • VRAX $9.00
  • Technical
  • Relative Strength Index (RSI)
  • AZTR 39.89
  • VRAX 34.78
  • Support Level
  • AZTR $0.28
  • VRAX $1.10
  • Resistance Level
  • AZTR $0.35
  • VRAX $1.35
  • Average True Range (ATR)
  • AZTR 0.03
  • VRAX 0.09
  • MACD
  • AZTR -0.00
  • VRAX 0.00
  • Stochastic Oscillator
  • AZTR 34.45
  • VRAX 19.44

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Share on Social Networks: